Browse studies

Find your next paid study

5 recruiting studies matching your filters

Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gath…

Non-Small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02146170

Phase 1

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and …

Solid Tumor CancerLocally AdvancedMetastatic Solid Tumors+5 more

Estimated

~$10 – $8,750

Avenzo Therapeutics, Inc.NCT07038343

Phase 2

A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma

Background: There are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers w…

Thymic Epithelial TumorRecurrent ThymomaThymic Cancer

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05104736

Phase 1

Allogeneic Stem Cell Transplantation Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion With Zoledronic Acid in Combination to Treat Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory Solid Tumors

Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced t…

NeuroblastomaRhabdomyosarcomaSynovial Sarcoma+11 more

Estimated

~$10 – $6,250

University of FloridaNCT06625190

Phase 2

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, f…

Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma+7 more

Estimated

~$10 – $7,500

Ira WinerNCT04055649